Bacteriophage compositions

Patent metadata

Field	Value
Publication number	US-12337020-B2
Application number	US-201917047611-A
Country	US
Kind code	B2
Filing date	Apr 17, 2019
Priority date	Apr 18, 2018
Publication date	Jun 24, 2025
Grant date	Jun 24, 2025

Abstract

The present invention relates to a bacteriophage composition comprising at least one bacteriophage species, at least one α-linked polymeric glucose and at least one polyol. In certain embodiments, the α-linked polymeric glucose has a mean molecular weight of greater than 10 kDa.

First claim

The invention claimed is:

1. A bacteriophage composition comprising:
at least one bacteriophage species,
at least one α-linked polymeric glucose,
at least one polyol, wherein the polyol is sucrose or sorbitol,

and optionally other ingredients selected from the group of buffer salts, electrolytes and surfactants, and wherein the weight ratio of the α-linked polymeric glucose to the polyol is about 4:6 to 8:2.

2. The bacteriophage composition according to claim 1 , wherein the α-linked polymeric glucose has a mean molecular weight from about 10 kDa to 1000 kDa, or from about 30 kDa to about 1000 kDa, or from about 150 kDa to about 800 kDa.

3. The bacteriophage composition according to claim 1 in the form of a dry composition, wherein the water content is less than 10% w/w, or less than 8% w/w, or less than 5% w/w, or less than 4% w/w.

4. A dry bacteriophage composition according to claim 3 , obtainable by spray drying a liquid composition.

5. The bacteriophage composition according to claim 1 , wherein one or more of the bacteriophage species are selected from the group of Caudovirales.

6. The bacteriophage composition according to claim 1 , wherein the α-linked polymeric glucose is selected from the group of dextrans and starches.

7. The bacteriophage composition according to claim 6 , wherein the α-linked polymeric glucose is a modified starch.

8. The bacteriophage composition according to claim 6 , wherein the α-linked polymeric glucose is a dextran.

9. A method of treating a bacterial infection comprising
administering to an animal or human patient in need of such a treatment a unit dose of the dry bacteriophage composition according to claim 3 , or
administering to an animal or human patient in need of such a treatment a unit dose of a reconstituted liquid bacteriophage composition obtainable by reconstituting the dry composition according to claim 3 in a pharmaceutically acceptable liquid.

10. A method for stabilizing a bacteriophage species during spray drying, the method comprising spray drying a bacteriophage species in combination with an α-linked polymeric glucose with a mean molecular weight of from about 10 kDa to about 1000 kDa, and a polyol, wherein the polyol is sucrose or sorbitol, and wherein the weight ratio of the α-linked polymeric glucose to the polyol is about 4:6 to 8:2.

11. The method of claim 10 , wherein the α-linked polymeric glucose is a hydroxyethyl starch or a dextran.

12. A process of preparing a dried bacteriophage composition comprising at least step 1 and step 2, involving preparing in step 1 a composition in an evaporable liquid comprising:
at least one bacteriophage species,
at least one α-linked polymeric glucose,
at least one polyol, wherein the polyol is sucrose or sorbitol,

and optionally other ingredients selected from buffer salts, electrolytes and surfactants, wherein the weight ratio of the α-linked polymeric glucose to the polyol is about 4:6 to 8:2, and
spray drying said liquid composition from step 1 in step 2 to obtain a dry bacteriophage composition.

13. The process according to claim 12 , wherein the α-linked polymeric glucose has a mean molecular weight of from about 10 kDa to about 1000 kDa or from about 40 kDa to about 1000 kDa, or from about 150 kDa to about 1000 kDa.

14. The process of claim 12 , wherein the log loss of activity (pfu/g) of at least three bacteriophage species from the liquid composition in step 1 to the dried particles in step 2 is less than 2, or less than 1.5 or less than 1.1.

15. The bacteriophage composition according to claim 5 , wherein one or more of the bacteriophage species are selected from the subgroups of Myoviridae, Podoviridae, Siphoviridae or mixtures thereof.

16. The bacteriophage composition according to claim 7 , wherein the α-linked polymeric glucose is a hydroxyalkyl starch.

17. The bacteriophage composition according to claim 16 , wherein the α-linked polymeric glucose is a hydroxyethyl starch.

18. The method of claim 10 , wherein the α-linked polymeric glucose has a mean molecular weight of from about 40 kDa to about 1000 kDa.

19. The method of claim 10 , wherein the α-linked polymeric glucose has a mean molecular weight of from about 150 kDa to about 1000 kDa.

20. The bacteriophage composition according to claim 3 , wherein the composition maintains stable activity of the bacteriophage species during storage at 25° C. and 60% relative humidity over 1 month characterized by a log loss of activity of less than about 2 to less than about 0.5 pfu/g, over 3 months characterized by a log loss of activity of less than about 5 to less than about 0.8 pfu/g, or over 6 months characterized by a log loss of activity of less than about 5 to less than about 1.

Assignees

• Takeda Gmbh
• Takeda Pharmaceuticals Co

Inventors

• Rast Markus
• Rodriguez-Morillas Sergio
• Iida Tomomine

Classifications

• C12N2795/10332

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title

• C12N2795/10232

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title

• C12N2795/10132

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title

• A61K9/1652

  Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623) · CPC title

• A61K9/1623

  Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules · CPC title